I t has been clearly demonstrated that concomitant enteral feedings alter the bioavailability of enterally administered phenytoin. [1] [2] [3] [4] This is clinically significant as phenytoin is a drug with a narrow therapeutic range that exhibits dose-dependent pharmacokinetics. It is possible that this phenomenon is due to a physicochemical interaction between phenytoin and feeding-formula proteins. Hooks et al. 5 demonstrated that phenytoin in suspension binds to proteins in commercially available feeding formulas; the percentage of free phenytoin recovered from a feeding formula increased with increased phenytoin concentration and decreased with increased feedingformula volume. They found a mean ± S.D. recovery of 37% ± 2.8% of phenytoin in the presence of the casein-based feeding-formula Osmolite. Smith et al. 6 demonstrated phenytoin recoveries of 81.2%, 57.4%, and 52.5% from mixtures of phenytoin and solutions of calcium caseinates, sodium caseinates, and calciumsodium caseinates, respectively.
The purpose of this study was to compare the recovery of phenytoin from different phenytoin formulations (suspension versus chewable tab-Abstract: The recovery of phenytoin from mixtures containing different phenytoin formulations and protein mixtures was studied.
Three phenytoin solutions (40 mg/µL) were prepared, each in triplicate, from phenytoin tablets, phenytoin suspension, and bulk phenytoin powder. These solutions were mixed with equivalent volumes of two commercially available feeding formulas (Replete and Ultracal) and two isolated protein mixtures (casein protein mixture and whey protein isolates mixture) and placed in ultrafiltration tubes. The mixtures were centrifuged, and phenytoin recovery was determined by using highperformance liquid chromatography. Control data were also obtained before and after the experiment.
There was no difference in phenytoin recovery when comparing phenytoin tablets versus phenytoin suspension in any of the protein media. There was a significant difference in phenytoin recovery when comparing the standard phenytoin solution mixed with Replete (32.51%) versus Ultracal (37.71%). There was also a significant difference in recovery when comparing the standard solution mixed with the calcium caseinate mixture (48.41%) versus the whey protein isolates mixture (82.01%). While the difference in recovery between Replete and Ultracal was expected, the significantly higher recovery of phenytoin from the whey protein mixture versus the calcium caseinate mixture indicated a much lower binding affinity between phenytoin and whey protein than with phenytoin and casein.
The recovery of unbound phenytoin from feeding formulas and solutions of protein isolates did not differ with phenytoin formulations. Ultracal had a lower level of binding to phenytoin than Replete; whey protein had a lower level of binding than casein.
Index terms: Anticonvulsants; Binding; Casein; Nutrition; Phenytoin; Proteins; Whey Am J Health-Syst Pharm. 2003; 60:1850-2 lets) in mixtures with different feeding formulas or solutions of protein isolates (casein protein solution and whey protein isolates solution). We also compared the recovery of phenytoin from a standard phenytoin solution in mixtures with these four liquids.
Methods
Preparation of phenytoin solutions. Phenytoin recovery from each mixture was determined by a modification of the technique described by Hooks et al. 5 Three phenytoin solutions were prepared, each in tripli-cate, from phenytoin chewable tablets, a phenytoin suspension, b and bulk phenytoin powder. c In a 50-mL volumetric flask, one crushed 50-mg phenytoin chewable tablet was dispersed in 50 mL of a 50:50 solution of methanol and deionized water and mixed with a vortex mixer for five minutes. In a 25-mL volumetric flask, 1 mL of phenytoin acid suspension (25 mg/mL) was diluted to 25 mL with a 50:50 solution of methanol and deionized water and mixed with a vortex mixer for five minutes. In a 25-mL volumetric flask, 25 mg of phenytoin was diluted to 25 mL with a 50:50 solution of methanol and deionized water and mixed with a vortex mixer for five minutes. The final nominal concentration of all solutions was 1 mg/mL.
Mixture with formulas and protein isolates. The commercially available feeding formulas used in this study were the casein-based formulas Replete d and Ultracal. e The interaction between phenytoin and isolated protein components of commercially available feeding formulas and nutritional supplements, calcium caseinates f and whey protein isolates, g was also studied. In these cases, isolated proteins were mixed in pH-adjusted water in equivalent concentrations to that contained in Ultracal (45 mg/mL).
One milliliter of each phenytoin solution was withdrawn and diluted to 25 mL in deionized water and mixed in a vortex mixer for two minutes. Five milliliters of the resulting solution was mixed in Replete, Ultracal, an aqueous calcium caseinate solution, and an aqueous whey protein solution to yield a total volume of 10 mL in a 10-mL volumetric flask, resulting in a theoretical phenytoin concentration of 20 µg/mL. Each mixture was placed in an ultrafiltration tube and centrifuged at 1520g for 60-75 minutes. These mixtures were then filtered through an ultrafiltration membrane h that retained protein-bound phenytoin but al-lowed unbound phenytoin to pass through; 500-750 µL of the ultrafiltrate was collected and its concentration was analyzed.
The concentration of unbound phenytoin from each resulting ultrafiltrate was measured in triplicate samples. An additional sample was taken from one of the ultrafiltrates at random to obtain 10 samples of every possible mixture. Control solutions containing the same final theoretical concentration of phenytoin (20 µg/ mL) in pH-adjusted deionized water (pH 6.7-6.8) were prepared using both phenytoin suspension and tablets to rule out adsorption to the ultrafiltration tubes.
Assay methods and statistics. Phenytoin concentration was determined by using a modified version of Miller and Strom's 7 highperformance liquid chromatography (HPLC) method. HPLC equipment consisted of a Hewlett-Packard ChemStation i and a 15-cm C18 column j with a diameter of 4.6 mm. The mobile phase was a 50:50 ratio of methanol and water. The detection wavelength was set at 220 nm. The flow rate was 0.8 mL/min, and the injection volume was 20 µL. Statistical analysis of the results was conducted using Student's t test with an a priori significance level of 0.05.
Results and discussion
Analysis of the control solutions of phenytoin showed a nearly 100% recovery after ultrafiltration. Control data were obtained before and after the experimental portion of the study. The control data are displayed in Table 1. A two-tailed t test for independent samples showed no significant difference in phenytoin recovery between the two control mixtures in either set of measurements.
The average recovery of phenytoin from the tablet-Ultracal mixture was 38.41%, compared with 37.41% recovery from the phenytoin suspension-Ultracal mixture ( Table 2 ). The average recovery of pheny-toin from the tablet-Replete mixture was 31.82%, compared with 33.13% recovery from the phenytoin suspension-Replete mixture. A twotailed t test for independent samples demonstrated no significant difference in the recovery of phenytoin when comparing the recovery of phenytoin from the respective formulations and feeding formula mixtures.
The average recovery of phenytoin from the tablet-casein mixture was 48.49%, compared with 48.73% recovery from the phenytoin suspension-casein mixture ( Table  2 ). The average recovery of phenytoin from the tablet-whey protein mixture was 82.37%, compared with 82.46% recovery from the phenytoin suspension-whey protein mixture. Neither difference was significant.
The average recovery of phenytoin from the phenytoin standard-Ultracal mixtures was significantly greater than that from the phenytoin standard-Replete mixtures (p < 0.05) ( Table 2) . A comparison of phenytoin standard from its mixture with calcium caseinates and whey protein solutions revealed that the recovery of unbound phenytoin was significantly greater from the phenytoin-whey protein mixture (p < 0.05).
The ultrafiltration experiments revealed no significant difference in phenytoin recovery from any of the mixtures when comparing different formulations of phenytoin (suspension and tablets). However, the average recovery of phenytoin from the standard phenytoin-Ultracal mixture was greater than that from the phenytoin standard-Replete mixture. This is not surprising because both feeding formulas contain casein as their main protein source, and Replete has a higher protein concentration than does Ultracal (62.4 versus 45 mg/mL). Hooks et al. 5 demonstrated an inverse relationship between phenytoin recovery and the amount of protein in the phenytoinfeeding formula mixtures. Our results confirmed these findings.
The difference in phenytoin recovery from mixtures with protein isolate solutions indicates that phenytoin has a lower affinity for binding whey protein than for calcium caseinates. It is possible that a feeding formula containing whey protein as its primary protein source would have less effect on the bioavailability of phenytoin in the presence of the formula when adminis-tered through enteral feeding tubes. Further research is required to confirm this hypothesis.
Conclusion
The recovery of unbound phenytoin from feeding formulas and solutions of protein isolates did not differ with phenytoin formulation. Ultracal had a lower level of binding to phenytoin than Replete; whey pro-tein had a lower level of binding than casein. 
